Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences' Lead Medicine into Advanced Clinical Trials
S tudy conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus
Article content
Article content
LONDON — VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials.
Article content
'These positive results underline the effectiveness of our human virus challenge model to rapidly assess clinical efficacy of novel medicines early in their clinical development pathway,' said Professor Sebastian Johnston, Co-founder and CMO at Virtus.
Article content
Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic obstructive lung disease. 'Before advancing vapendavir into clinical trials testing vapendavir on thousands of patients costing tens of millions of dollars, it was critical to demonstrate beneficial effects of the drug in a proof-of-concept study,' said Dr. Brett Giroir, CEO of Altesa and former US Assistant Secretary for Health and Acting FDA Commissioner. 'After literally searching the globe, we determined that VirTus was the only place that could safely, effectively, and reliably conduct this study on actual volunteers with COPD.'
Article content
The randomised, placebo-controlled study enrolled and evaluated 40 volunteers with COPD, the 3 rd leading cause of death worldwide. Pre-screened COPD patients were challenged with a known-to-be safe strain of rhinovirus and randomized after onset of symptoms. Recruitment involved contacting over 10,000 potential volunteers primarily through targeted social media campaigns, highlighting the innovative approach VirTus employs to ensure efficient and successful participant engagement.
Article content
'These positive results underline the effectiveness of our human virus challenge model to rapidly assess clinical efficacy of novel medicines early in their clinical development pathway,' said Professor Sebastian Johnston, Co-founder and Chief Medical Officer (CMO) at VirTus. 'This approach allows our biotech and pharmaceutical industry partners to gain early, meaningful clinical data, helping them to make confident go/no-go decisions in their drug development pipeline.'
Article content
VirTus' human virus challenge model offers sponsors the opportunity to evaluate treatments in a controlled environment, significantly reducing uncertainty, time and cost associated with much larger, traditional early clinical development studies.
Article content
'By leveraging the wealth of experience of Professor Johnston and the VirTus team, we have learned how to best deploy vapendavir so that is has the best chance of improving the lives of people with COPD – which is our ultimate goal and one that I have dedicated my career to achieving,' said Dr. Kate Knobil, CMO at Altesa and former CMO of GSK.
Dr Michael Edwards, Co-founder and Managing Director at VirTus, added, 'We're delighted to support Altesa BioSciences in achieving these encouraging results with vapendavir. This successful collaboration showcases the strength and reliability of our human challenge studies, reinforcing our mission to accelerate innovative treatments for respiratory illnesses worldwide.'
Article content
VirTus Respiratory Research Ltd is a CRO co-led by Professor Sebastian Johnston and Dr. Michael Edwards, both of Imperial College London, United Kingdom. VirTus is dedicated to accelerating the development of novel therapies for the treatment and prevention of respiratory virus infections, which are the leading cause of acute attacks (exacerbations) in chronic respiratory diseases such as asthma, COPD and bronchiectasis. VirTus conducts both pre-clinical and early-phase clinical studies, specialising in human virus challenge models to generate high-quality data that supports the advancement of new therapeutics into later-stage development.
Article content
The rhinovirus challenge model
Article content
At VirTus Respiratory Research Ltd, the rhinovirus challenge model is used to generate early signals of clinical efficacy in a tightly controlled, reproducible setting. By exposing volunteers to rhinovirus infection under monitored conditions, the model provides detailed assessment of how a treatment impacts symptoms, virus load and immune/inflammatory responses. For our partners, this model acts as a critical go/no-go decision maker ahead of much larger, costlier Phase 2b/3 trials. It helps answer key questions early, including clinical efficacy, dose selection and endpoint optimisation. Sponsors benefit from accelerated timelines, early go/no-go insights, de-risking development programs by identifying promising candidates, or ruling out ineffective ones, at an earlier stage, ultimately optimising resource allocation and increasing the likelihood of downstream success.
Article content
About Vapendavir
Article content
Vapendavir, taken orally in pill form, is a clinical-stage antiviral medicine with potent activity against 97% of rhinoviruses tested and other respiratory enteroviruses. It prevents the virus from entering human cells as well as preventing it from reproducing. Vapendavir is currently in advanced clinical trials for the treatment of rhinovirus infections in people living with COPD. Vapendavir has a similar mechanism of action to the FDA approved HIV capsid inhibitor, lenacapavir marketed by Gilead Sciences.
Article content
About COPD
Article content
COPD is a life-limiting chronic lung condition that affects hundreds of millions of people worldwide. COPD is now the third leading cause of death globally, with prevalence continuing to rise due to aging populations and ongoing exposure to risk factors such as smoking and air pollution. COPD imposes a huge burden on individuals and healthcare systems alike, with high morbidity due to progressive lung function decline and frequent exacerbations, alongside enormous ($49 billion in the US) healthcare costs associated with long-term treatment and prolonged and frequent hospital admissions.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
10 minutes ago
- CTV News
‘Grief and sadness': Animal lovers and activists protest dog testing outside St. Joseph's hospital
Animal lovers and activists protested animal mistreatment outside St. Joseph's hospital. CTV London's Brent Lale reports.
Globe and Mail
a day ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
a day ago
- CTV News
Canadian researchers have an eye on the sky, tracking contrails with cameras
Using a camera network, the researchers are tracking contrails to mitigate aviation-induced climate change. CTV London's Reta Ismail has the story. Researchers at Western University are tackling aviation-induced climate change – by using existing cameras to track contrails. They're called contrails short for condensation trails, visible in the sky. And according to scientists, these thin white trails impact the environment. 'Aviation is a significant source of climate change impact and a portion of that is not direct CO2 emissions, but the secondary effects that come from contrails,' said Denis Vida, a physics and astronomy professor at Western University. To mitigate the impact of contrails, a team of researchers from Western, along with the Global Meteor Network (GMN), is working with an experienced pilot to change the flying altitude of planes by using ground-based cameras to observe airplanes. 'Small percentage of flights, about 15 per cent, would need to make little corrections just in height that don't cost much to eliminate contrails entirely,' explained Vida. 'The major problem is that, there's no data to inform the models to send the airplanes in the right direction, and we're changing that with our project.' The project is now financially backed by Google and Breakthrough Energy. Vida founded and now coordinates GMN, a game-changing international collaboration that has more than 1,400 cameras globally to capture meteor events and now survey aircraft contrails. This project started after Luc Busquin, an experienced captain with Alaska Airlines and founder of ContrailCast, reached out to Vida about using a GMN meteor camera to observe contrails for climate impact research. 'This solution was answering a need from the contrails researchers that they needed to be able to associate contrails with flights, but they were not able to do. And this solution was an answer to the problem,' said Busquin. Vida says existing geostationary satellite systems on average only detect contrails 30 minutes after formation, limiting their utility for actionable mitigation strategies. GMN, with its global distribution of calibrated cameras that directly observe contrails as they are created, offers a unique opportunity. By the end of the year, the team hopes to deliver the first open-access dataset linking contrails with flights and atmospheric conditions. This will give air traffic controllers and various other stakeholders relevant information to re-organize the flow of flight patterns and create real change in future aircraft designs and technologies.
